NCT06270966

Brief Summary

The need to promote research in active aging trough multidisciplinary and innovative approaches is strongly indicated by the European Union. Our study aims to assess the feasibility and provide a preliminary measure of effectiveness for an intervention using immersive virtual reality (VR) technology for cognitive remediation (CR) in individuals with Mild Cognitive Impairment (MCI)

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2024

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 13, 2024

Completed
8 days until next milestone

First Posted

Study publicly available on registry

February 21, 2024

Completed
15 days until next milestone

Study Start

First participant enrolled

March 7, 2024

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2024

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2025

Completed
Last Updated

February 21, 2024

Status Verified

February 1, 2024

Enrollment Period

9 months

First QC Date

February 13, 2024

Last Update Submit

February 13, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Side effects; Dropout rates; Proportion of recruited participants among those considered eligible

    Feasibility will be assessed based on tolerability, including dropout rates and acceptability, which considers the proportion of recruited participants among those considered eligible and side effects.

    T0 (0 weeks); T1 (12 weeks)

Secondary Outcomes (13)

  • Short Form Health Survey, 12 items (SF-12)

    T0 (0 weeks); T1 (12 weeks); T2 (36 weeks); (72 weeks)

  • Brief Social Rhythms Scale (BSRS)

    T0 (0 weeks); T1 (12 weeks); T2 (36 weeks); (72 weeks)

  • Patient Health Questionnaire (PHQ-9)

    T0 (0 weeks); T1 (12 weeks); T2 (36 weeks); (72 weeks)

  • Generalized Anxiety Disorder-7 item (GAD-7)

    T0 (0 weeks); T1 (12 weeks); T2 (36 weeks); (72 weeks)

  • Addenbrooke's Cognitive Examination (ACE-R)

    T0 (0 weeks); T1 (12 weeks); T2 (36 weeks); (72 weeks)

  • +8 more secondary outcomes

Study Arms (2)

Virtual Reality Cognitive Remediation + treatment as usual

EXPERIMENTAL

15 Participants with more than 65 years and with MCI diagnosis will undergo a cognitive remediation program using fully immersive VR. Participants will continue with standard care during the experimental intervention

Device: Virtual Reality Cognitive Remediation

Treatment as usual

NO INTERVENTION

The control group, 15 participants with more than 65 years and with MCI diagnosis, will continue with standard care.

Interventions

Participants will undergo a 3-months cognitive remediation program using fully immersive VR with two sessions per week. Each session will last a maximum of sixty minutes and will be supervised by expert health professionals. The experimental group participated in an immersive VR-based CR program using the "CEREBRUM" software designed by clinicians and experts specializing in cognitive rehabilitation. CEREBRUM provides 52 exercises: Attention, Working Memory, Memory and Learning and Cognitive Estimates. The intervention included 24 sessions.

Virtual Reality Cognitive Remediation + treatment as usual

Eligibility Criteria

Age65 Years+
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)

You may qualify if:

  • age 65 and above, a diagnosis of MCI based on DSM-IV criteria \[American Psychiatric Association, 2000\]

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

San Giovanni di Dio Hospital

Cagliari, CA, 09100, Italy

Location

MeSH Terms

Conditions

Cognitive Dysfunction

Condition Hierarchy (Ancestors)

Cognition DisordersNeurocognitive DisordersMental Disorders

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Randomized Controlled Trial
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

February 13, 2024

First Posted

February 21, 2024

Study Start

March 7, 2024

Primary Completion

December 1, 2024

Study Completion

December 1, 2025

Last Updated

February 21, 2024

Record last verified: 2024-02

Locations